PathAI secures $60 million in Series B funding led by General Atlantic and existing investor General Catalyst

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

advertisement
Current Location:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Artificial Intelligence Homepage

OptraSCAN launches OS-SiA, a next-gen AI-enabled digital scanner

Paragon Biosciences launches Qlarity Imaging to advance first FDA-cleared artificial intelligence breast cancer diagnosis system

Medical imaging company Oxipit raises $1.7M seed round to bring AI into clinical radiology practice

Geisinger taps EarlySign for new range of AI solutions to identify patients at risk of high-burden diseases

iCAD’s ProFound AI for 2D mammography receives CE mark approval

FDA clears Koios DS Breast 2.0 to assist physicians with AI-based software

Waystar acquires Digitize.AI to automate prior authorization

New probe could help surgeons more accurately remove tumors

Microsoft And Providence St. Joseph Health announce strategic alliance to Accelerate the future of care delivery

Strategic Radiology adds Quinsite data analytics to preferred vendor list

PathAI secures $60 million in Series B funding led by General Atlantic and existing investor General Catalyst

Press releases may be edited for formatting or style
Boston, Massachusetts – PathAI, a global provider of artificial intelligence-powered technology for pathology, announced today that it has raised $60 million in Series B funding. The round was led by new investor General Atlantic, a leading global growth equity firm, with strong participation from General Catalyst and other existing investors. The new capital will fuel PathAI’s continued expansion as the company seeks to advance the medical discipline of pathology. General Atlantic Managing Director Dr. Michelle Dipp will be joining PathAI’s board of directors as the company advances its mission of offering faster, safer, and more powerful solutions for the diagnosis and sub-typing of diseases like cancer.

PathAI plans to use this new capital to enhance offerings to existing partners, drive continuous improvement of its flagship pathology research platform, meet market demands, and fuel research and development into new tools and medical devices. Its growing partnerships with leading global pharmaceutical companies seek to accelerate drug development in life-saving therapeutics, and its partnerships with leading diagnostic laboratories aim to support pathologists in bringing faster, more accurate, and more predictive diagnostics to patients.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



“Our goal has been clear since day one – a relentless drive to ensure patients get the right diagnosis and the most effective treatment. We’re looking forward to working with our partners to scale this effective approach across disease areas and around the world,” PathAI co-founder and Chief Executive Officer Dr. Andy Beck said. “The global network and deep expertise in technology and life sciences brought by General Atlantic, alongside the continued support of existing investors like General Catalyst, can only enhance our ability to effect change toward this major, impactful objective.”

“PathAI is a clear leader in the emerging digital pathology industry that is being disrupted by technology and machine learning,” said Dr. Michelle Dipp. “As we remain committed to supporting the next generation of life sciences companies, we’re thrilled to partner with PathAI, which seeks to address critical problems by bringing cutting edge storage, viewing, and AI-enabled analytics to help pathologists make fast, accurate, and consistent diagnoses.

“PathAI’s work could radically improve the accuracy and reproducibility of disease diagnosis and support the development of new medicines to treat those diseases,” said David Fialkow, Managing Director at General Catalyst. “GC is honored to once again back founders, Andy Beck and Aditya Khosla, Chief Business Officer Tiffany Freitas, Chairman Jeff Leiden, and the entire PathAI team. The positive – and global – impact of getting this right cannot be overstated. We think this is the team that has all the potential to bring these game-changing solutions to market.”
  Pages: 1 - 2 >>

Artificial Intelligence Homepage


You Must Be Logged In To Post A Comment